18 MSDㆍ16 Pfizerㆍ15 CKD drugs secure blockbuster status

Last year, a total of 10 pharmaceutical companies produced more than 10 blockbuster drugs(more than 10 billion won in annual sales).

According to IQVIA, 387 out of 28,000 medicines included in the IQVIA list last year recorded more than 10 billion won in annual sales.

By company, a total of 95 companies produced more than one blockbuster drugs, and 10 of them produced more than 10 blockbusters.

In contrast, 32 out of 95 companies, a little over a third, had only one blockbuster drug.

MSD had the largest number of blockbuster drugs with a total of 18. The number is down one compared to 2018.

Following MSD, Pfizer produced 16 blockbusters, one more than in 2018, and Chong Kun Dang produced 15 blockbusters, up by 3.

In the outpatient prescription data(UBIST), which vaccines and anti-cancer drugs prescribed in the hospital are not counted, domestic companies dominated the top spots, however, the foreign companies swept the top spots in IQVIA.

In addition to the three companies with more than 15 blockbuster drugs, Daewoong Pham, Sanofi, CJ HealthCare, AstraZeneca, Novartis produced 14, Hanmi Pharm produced 11 and GC Pharm produced 10 blockbusters.

Among them, the number of blockbuster drugs of Hanmi Pharm and GC Pharm increased to double digits from 9 in 2018.

On the other hand, JW Pharmaceutical, which produced 10 blockbusters in 2018, saw its number of blockbusters declined to 9, while Roche maintained 9 blockbusters.

It was followed by GSK, Takeda, Bayer and Boryung Pharmaceutical with 8. Dong-A ST, Ildong Pharmaceutical, Boehringer Ingelheim, Astellas, Handok produced 7 blockbusters.

In addition, Novo Nordisk, Dong Kook Pharm, Yuhan Corporation, Lilly, Janssen produced 6 blockbusters, and Gilead, SK Chemicals, Baxter also produced more than five blockbusters.